![Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)](/images/assets/d743d32f-3115-48ff-9697-2f2d56130701/small/14175.jpg)
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” This study synthesized and verified the structures of Setipiprant's major and minor metabolites, confirming their regio- and enantioselectivity from earlier proposals in a clinical study.
9 citations
,
December 2017 in “The Journal of Allergy and Clinical Immunology” This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.
25 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.
August 2025 in “JEADV Clinical Practice” In this case report, researchers documented a 71-year-old woman with both alopecia areata and bullous pemphigoid who showed significant improvement using dupilumab after other treatments failed, highlighting its potential for autoimmune diseases with overlapping inflammatory mechanisms.
March 2021 in “International Journal of Clinical Dermatology & Research” Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.